

Resource Summary Report

Generated by [kravitz2](#) on Aug 24, 2026

B6CBA-Tg(HDexon1)62Gpb/1J

RRID:IMSR_JAX:002810

Type: Organism

Proper Citation

RRID:IMSR_JAX:002810

Organism Information

URL: <https://www.jax.org/strain/002810>

Proper Citation: RRID:IMSR_JAX:002810

Description: Mus musculus with name B6CBA-Tg(HDexon1)62Gpb/1J from IMSR.

Species: Mus musculus

Synonyms: B6CBA-TgN(HDexon1)62Gpb. B6CBA-Tg(HDexon1)62oGpb/J

Notes: gene symbol note: huntingtin|transgene insertion 62; Gillian Bates; mutant strain: HTT|Tg(HDexon1)62Gpb

Affected Gene: huntingtin|transgene insertion 62; Gillian Bates

Genomic Alteration: transgene insertion 62; Gillian Bates

Catalog Number: JAX:002810

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: B6CBA-Tg(HDexon1)62Gpb/1J

Record Creation Time: 20250513T053635+0000

Record Last Update: 20260815T050545+0000

Ratings and Alerts

No rating or validation information has been found for B6CBA-Tg(HDexon1)62Gpb/1J.

No alerts have been found for B6CBA-Tg(HDexon1)62Gpb/1J.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 324 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#).

Jeon H, et al. (2026) Neuroprotective Effects of Transplanted Induced Pluripotent Stem Cell-Derived Neural Precursors in Huntington's Disease Models. International journal of stem cells, 19(2), 172.

Rabenius A, et al. (2026) Transcriptional responses to proteotoxic stressors are profoundly diverse and tissue-specific. Cell stress & chaperones, 31(2), 100146.

Lee LKC, et al. (2026) Small Gold Nanoparticles Alleviate Huntington's Disease via Modulating p38 γ Mitogen-Activated Protein Kinase and Pyruvate Dehydrogenase Kinase 1. ACS nano, 20(1), 683.

Hu D, et al. (2026) A small-molecule stabilizer of the calpastatin-calpain-2 complex restores mitochondrial function and mitigates neurodegeneration. Science advances, 12(13), eaeb1174.

Lu PC, et al. (2026) PROTAC-Mediated Degradation of mHTT Aggregates Attenuates Neurotoxicity in Cellular and R6/2 Mouse Models of Huntington's Disease. Journal of the American Chemical Society, 148(8), 8107.

Okamura-Oho Y, et al. (2026) Topological modeling of gene expression in the brain with Huntington's disease reveals selective disruption of co-expression network. Scientific reports, 16(1).

Miranda DR, et al. (2026) Integrated effects of altered action potentials and calcium release on skeletal muscle force generation in transgenic Huntington's disease mice. Pflugers Archiv : European journal of physiology, 478(2), 24.

Nguyen KQ, et al. (2026) Fingolimod Effects on Motor Function and BDNF-TrkB Signaling in a Huntington's Mouse Model Are Disease-Stage-Dependent. International journal of molecular sciences, 27(1).

Jauhari A, et al. (2026) Metabolic reprogramming is critical to microglial activation in Huntington's disease. JCI insight, 11(10).

Tung YS, et al. (2025) Insulin-like growth factor 2 reduces Huntington's disease aggregates via AKT and NF- κ B signaling in huntington's disease. Cell & bioscience, 15(1), 109.

Bosica M, et al. (2025) Coiled-Coil Structures Mediate the Intercellular Propagation of Huntingtin. *International journal of molecular sciences*, 26(17).

Pradhan S, et al. (2025) Huntingtin preserves mitochondrial genome integrity in neurons, which is impaired in Huntington's disease. *bioRxiv : the preprint server for biology*.

Frosch M, et al. (2025) Microglia-neuron crosstalk through Hex-GM2-MGL2 maintains brain homeostasis. *Nature*, 646(8086), 913.

Oberländer K, et al. (2025) Inhba, Homer1 and Bdnf are major targets of transcriptomic dysregulation by neurodegenerative disease-associated excitotoxic NMDA receptor signaling. *Communications biology*, 8(1), 1743.

Tan K, et al. (2025) Treatment of Huntington's disease with a pan-HTT-targeting CRISPR nuclease. *bioRxiv : the preprint server for biology*.

Cheng CY, et al. (2025) The therapeutic potential of (R)-carvedilol in Huntington's disease through enhancement of autophagy-lysosomal pathway via GSK-3 β inhibition. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, 22(3), e00557.

Rusmini P, et al. (2025) Impairment of lysosomal quality control in Huntington disease. *Cell death & disease*, 16(1), 762.

Jiménez-Jiménez FJ, et al. (2025) Oxidative Stress in Huntington's Disease. *Biomolecules*, 15(4).

Kang YK, et al. (2025) Emergence of CpG-cluster blanket methylation in aged tissues: a novel signature of epigenomic aging. *Nucleic acids research*, 53(9).

Sapp E, et al. (2025) Mutant huntingtin exon 1 protein detected in mouse brain with neoepitope antibody: effects of CAG repeat expansion, MutS Homolog 3 silencing and aggregation. *Brain communications*, 7(5), fcaf314.